PharmaReports: Neurodegenerative & Neuroelectrophysiological Disorders
LeadDiscovery offers full reports in selected areas of the pharmaceutical and biotech sector.
Each of the reports below has been especially selected by LeadDiscovery. Browse the reports or try our search engine.
This channel focusses on the chronic neurodegenerative disorders. Reports investigating memory/cognitive decline are also listed here unless they are clearly unrelated to neurodegeneration. In addition, reports relating to acute neurodegeneration such as stroke and cerebral hemorrhage can be included here.
Showing results 101 - 142 of 142
- Neurology Devices Market Outlook in Japan to 2016 - Neurostimulation Devices, Interventional Neurology and Others
- CNS Clinical Trials: World Market Prospects 2011-2026
- US Pharmaceutical Market Outlook 2011-2021
- Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions
- Epidemiology: Parkinson's Disease
- Future Directions in Regenerative Medicine
- UpdatesPlus Nicotinic Receptors - Current Research and Development - March 2011
- Pharmaceutical Key Trends 2011 – Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
- Pharmaceutical Key Trends 2011 – Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits
- R&D Trends: Multiple Sclerosis (MS) - Progressive subtypes remain underserved in expansive pipeline
- UpdatesPlus Nicotinic Receptors and Addiction - Current Research and Development - April/May 2011
- Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
- Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure
- Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development
- Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies
- Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
- Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies
- Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
- Neupro (Parkinson's Disease) - Analysis and Forecasts to 2020
- Eldepryl (Parkinson's Disease) – Analysis and Forecasts to 2012
- Azilect (Parkinson's Disease) – Analysis and Forecasts to 2020
- Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth
- Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
- GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing
- Neurology Devices Market to 2017 - High Potential for Usage of Neurostimulation Devices in Multiple Neurological Disorders to Drive Market Growth
- Apokyn (Parkinson's Disease) – Analysis and Forecasts to 2020
- Tasmar (Parkinson's Disease) – Analysis and Forecasts to 2020
- Stalevo (Parkinson's Disease) – Analysis and Forecasts to 2020
- Comtan (Parkinson's Disease) - Analysis and Forecasts to 2020
- KW-6002 (Parkinson's Disease) – Analysis and Forecasts to 2020
- IPX066 (Parkinson's Disease) – Analysis and Forecasts to 2020
- Trerief (Parkinson's Disease) – Analysis and Forecasts to 2020
- Requip XL (Parkinson's Disease) – Analysis and Forecasts to 2020
- Mirapex (Parkinson's Disease) – Analysis and Forecasts to 2020
- Mirapex ER (Parkinson's Disease) – Analysis and Forecasts to 2020
- Pardoprunox (Parkinson's Disease) – Analysis and Forecasts to 2020
- Preladenant (Parkinson's Disease) – Analysis and Forecasts to 2020
- Safinamide (Parkinson's Disease) – Analysis and Forecasts to 2020
- Zelapar (Parkinson's Disease) – Analysis and Forecasts to 2020
- Requip (Parkinson's Disease) – Analysis and Forecasts to 2020
- Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Browse our theraputic areas for other entries:
- Oncology
- Cancer Immunotherapy
- Immunology & Inflammatory Diseases
- Infectious Diseases
- Psychiatric, Addictive & Sleep Disorders
- Pain
- Neurodegenerative & Neuroelectrophysiological Disorders
- Metabolic & Hormonal Disorders
- Cardiovascular Disorders
- GenitoUrinary Tract Disorders
- Technology
- Diagnostics & Devices
- Other Theraputic Areas, Pharmaceutical Strategy and Development